Hans-Peter Gerber
Known title: CHIEF SCIENTIFIC OFFICERCIK: 0001992979
Hans-Peter Gerber's purchase track record
Hans-Peter Gerber has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/15/2025 | STRO | $14K | +62.3% | +281.7% | +5.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| STRO | ▲ Buy | Option Exercise | 3,750 | $0 | 9/18/2026 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 1,345 | $21K | 9/18/2026 | View on chart |
| STRO | ▲ Buy | Option Exercise | 2,843 | $0 | 3/2/2026 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 1,170 | $24K | 3/2/2026 | View on chart |
| STRO | ▲ Buy | Option Exercise | 1,125 | $0 | 3/1/2026 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 463 | $9K | 3/1/2026 | View on chart |
| STRO | ▲ Buy | Open Market | 17,000 | $14K | 10/15/2025 | View on chart |
| STRO | ▲ Buy | Option Exercise | 37,500 | $0 | 9/18/2025 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 13,417 | $12K | 9/18/2025 | View on chart |
| STRO | ▲ Buy | Option Exercise | 11,250 | $0 | 3/1/2025 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 4,621 | $7K | 3/1/2025 | View on chart |
| STRO | ▲ Buy | Option Exercise | 37,500 | $0 | 9/18/2024 | View on chart |
| STRO | ▼ Sell | Tax Withholding | 13,380 | $53K | 9/18/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Sutro Biopharma Names New Business Development SVP
Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.
Sutro Biopharma Names New Business Development SVP. Sutro Biopharma has appointed Lucas Donigian as Senior Vice President of Business Development. This leadership addition is relevant for investors tracking the company's commercial strategy and partnership efforts. The move provides context for the stock's current trading levels and analyst expectations.